ClinVar Genomic variation as it relates to human health
NM_000512.5(GALNS):c.239C>T (p.Ser80Leu)
criteria provided, multiple submitters, no conflicts. Learn more about how ClinVar calculates review status.
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000512.5(GALNS):c.239C>T (p.Ser80Leu)
Variation ID: 521930 Accession: VCV000521930.17
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 16q24.3 16: 88842711 (GRCh38) [ NCBI UCSC ] 16: 88909119 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 15, 2018 Apr 13, 2025 Nov 24, 2023 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000512.5:c.239C>T MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000503.1:p.Ser80Leu missense NM_001323543.2:c.-311-740C>T intron variant NM_001323544.2:c.257C>T NP_001310473.1:p.Ser86Leu missense NC_000016.10:g.88842711G>A NC_000016.9:g.88909119G>A NG_008667.1:g.19256C>T - Protein change
- S80L, S86L
- Other names
- -
- Canonical SPDI
- NC_000016.10:88842710:G:A
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
Trans-Omics for Precision Medicine (TOPMed) 0.00001
The Genome Aggregation Database (gnomAD), exomes 0.00000
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
GALNS | Gene associated with autosomal recessive phenotype | No evidence available |
GRCh38 GRCh37 |
1145 | 1457 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Likely pathogenic (1) |
criteria provided, single submitter
|
Nov 14, 2017 | RCV000622775.4 | |
Pathogenic (1) |
criteria provided, single submitter
|
May 13, 2019 | RCV001193736.1 | |
Pathogenic/Likely pathogenic (4) |
criteria provided, multiple submitters, no conflicts
|
Nov 24, 2023 | RCV001578493.11 | |
GALNS-related disorder
|
Likely pathogenic (1) |
criteria provided, single submitter
|
Jun 7, 2023 | RCV003420080.4 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Likely pathogenic
(Nov 14, 2017)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: clinical testing
|
Inborn genetic diseases
Affected status: yes
Allele origin:
germline
|
Ambry Genetics
Accession: SCV000742739.4
First in ClinVar: Apr 15, 2018 Last updated: Apr 13, 2025 |
Number of individuals with the variant: 1
Sex: male
Ethnicity/Population group: Asian
|
|
Pathogenic
(May 13, 2019)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: clinical testing
|
Morquio syndrome
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV001362798.1
First in ClinVar: Jun 22, 2020 Last updated: Jun 22, 2020 |
Comment:
Variant summary: GALNS c.239C>T (p.Ser80Leu) results in a non-conservative amino acid change located in the Sulfatase, N-terminal domain of the encoded protein sequence. Five of … (more)
Variant summary: GALNS c.239C>T (p.Ser80Leu) results in a non-conservative amino acid change located in the Sulfatase, N-terminal domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 247532 control chromosomes. c.239C>T has been reported in the literature in individuals affected with Mucopolysaccharidosis Type IVA (Morquio Syndrome A, Tomatsu_2005, Pollard_2013, Tapiero-Rodriguez_2018). These data indicate that the variant is likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal expression/activity (Tomatsu_2006, Tapiero-Rodriguez_2018). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as pathogenic. (less)
|
|
Likely pathogenic
(Feb 01, 2021)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: research
|
Mucopolysaccharidosis, MPS-IV-A
Affected status: yes
Allele origin:
germline
|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova
Accession: SCV001547626.3
First in ClinVar: Aug 25, 2021 Last updated: Oct 30, 2021 |
Comment:
In vitro and vivo functional studies supportive of a damaging effect on the gene product (low to null enzymatic activity in homozygotes; low to null … (more)
In vitro and vivo functional studies supportive of a damaging effect on the gene product (low to null enzymatic activity in homozygotes; low to null in vitro enzymatic activity; PS3_moderate); the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_strong); very low frequency in gnomAD v2.1.1 (PM2_moderate); multiple lines of computational evidence support a deleterious effect on the gene (PP3_supporting) (less)
|
|
Likely pathogenic
(Nov 07, 2021)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-IV-A
Affected status: no
Allele origin:
germline
|
Genome-Nilou Lab
Accession: SCV002045036.1
First in ClinVar: Jan 03, 2022 Last updated: Jan 03, 2022 |
|
|
Pathogenic
(Nov 24, 2023)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-IV-A
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV002228773.4
First in ClinVar: Mar 28, 2022 Last updated: Feb 25, 2025 |
Comment:
This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 80 of the GALNS protein (p.Ser80Leu). … (more)
This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 80 of the GALNS protein (p.Ser80Leu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with mucopolysaccharidosis type IVA (PMID: 9375852, 22976768, 25545067, 29731656). ClinVar contains an entry for this variant (Variation ID: 521930). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALNS protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GALNS function (PMID: 9375852). For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Likely pathogenic
(Jun 07, 2023)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: clinical testing
|
GALNS-related condition
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV004108330.1
First in ClinVar: Nov 20, 2023 Last updated: Nov 20, 2023 |
Comment:
The GALNS c.239C>T variant is predicted to result in the amino acid substitution p.Ser80Leu. This variant was reported in homozygous and compound heterozygous state in … (more)
The GALNS c.239C>T variant is predicted to result in the amino acid substitution p.Ser80Leu. This variant was reported in homozygous and compound heterozygous state in multiple individuals with Mucopolysaccharidosis IVA (Tomatsu et al. 1997. PubMed ID: 9375852; Pachajoa et al. 2021. PubMed ID: 34542925; Pollard et al. 2012. PubMed ID: 22976768; Tapiero-Rodriguez et al. 2018. PubMed ID: 29731656). In vitro and in vivo studies show that this variant results in significantly reduced enzymatic activity (Tomatsu et al. 1997. PubMed ID: 9375852; Tapiero-Rodriguez et al. 2018. PubMed ID: 29731656). This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-88909119-G-A). This variant is interpreted as likely pathogenic. (less)
|
|
Pathogenic
(-)
C
Contributing to aggregate classification
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-IV-A
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Neuberg Centre For Genomic Medicine, NCGM
Accession: SCV005061169.1
First in ClinVar: Jun 17, 2024 Last updated: Jun 17, 2024 |
Comment:
The observed missense variant c.239C>T(p.Ser80Leu) in GALNS gene has been reported previously in homozygous, compound heterozygous state in individuals with mucopolysaccharidosis IVA (Tapiero-Rodriguez SM, et … (more)
The observed missense variant c.239C>T(p.Ser80Leu) in GALNS gene has been reported previously in homozygous, compound heterozygous state in individuals with mucopolysaccharidosis IVA (Tapiero-Rodriguez SM, et al., 2018, Pollard LM, et al., 2013). Experimental studies have shown that this missense change affects GALNS function (Tomatsu S, et al., 1997). The c.239C>T variant has 0.0004% allele frequency in gnomAD Exomes. This variant has been reported to the ClinVar database as Pathogenic/Likely Pathogenic. The amino acid Serine at position 80 is changed to a Leucine changing protein sequence and it might alter its composition and physico-chemical properties. Multiple lines of computational evidence (Polyphen, SIFT and MutationTaster) predict a damaging effect on protein structure and function for this variant. The amino acid change p.Ser80Leu in GALNS is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. (less)
Clinical Features:
Abnormality of the musculoskeletal system (present)
|
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants. | Zanetti A | Human mutation | 2021 | PMID: 34387910 |
Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA. | Tapiero-Rodriguez SM | The application of clinical genetics | 2018 | PMID: 29731656 |
Optimizing the molecular diagnosis of GALNS: novel methods to define and characterize Morquio-A syndrome-associated mutations. | Caciotti A | Human mutation | 2015 | PMID: 25545067 |
Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A. | Olarte-Avellaneda S | Molecular biology reports | 2014 | PMID: 25287660 |
GALNS mutations in Indian patients with mucopolysaccharidosis IVA. | Bidchol AM | American journal of medical genetics. Part A | 2014 | PMID: 25252036 |
Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. | Morrone A | Molecular genetics and metabolism | 2014 | PMID: 24726177 |
Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. | Pollard LM | Journal of inherited metabolic disease | 2013 | PMID: 22976768 |
Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. | Tomatsu S | Current pharmaceutical biotechnology | 2011 | PMID: 21506915 |
Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA gene. | Tomatsu S | Molecular genetics and metabolism | 2006 | PMID: 16837223 |
Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). | Tomatsu S | Human mutation | 2005 | PMID: 16287098 |
Fourteen novel mucopolysaccharidosis IVA producing mutations in GALNS gene. | Tomatsu S | Human mutation | 1997 | PMID: 9375852 |
click to load more citations click to collapse |
Text-mined citations for rs1209154325 ...
HelpRecord last updated Apr 13, 2025
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.